Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Recruiting
N/A
Interventional Study
Malignant Pleural Mesothelioma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 30 – 85
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 20 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathpri…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Aged 30-85 years
* No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
* Recent diagnosis of MPM
* Documented, signed, and dated informed consent, obtained before any procedures, for …
Contacts
David Jones, MD
212-639-6428
CONTACT